TerminatedNot Applicable

Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration

Stopped: Challenging Enrollment

United States1 participantsStarted 2019-05-29

Plain-language summary

This study will define the limits of subretinal hemorrhage parameters that are consistent with a good visual outcome with aggressive anti-VEGF treatment in patients with neovascular age-related macular degeneration (NVAMD).

Who can participate

Age range50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Signed informed consent and authorization of use and disclosure of protected health information * Age 50 years or older * Presence of subretinal hemorrhage (SRH) involving the fovea in patients with NVAMD including polypoidal choroidal vasculopathy (PCV) Exclusion Criteria: * SFH in the study eye due to causes other than NVAMD * Media opacity due to concurrent vitreous hemorrhage or cataracts that preclude adequate imaging * Substantial loss of VA due to condition other than AMD * Limited visual potential from substantial atrophy or fibrosis in fovea * Poor visual potential with known permanent reduction in visual acuity prior to SFH

What they're measuring

Correlation between hemorrhage characteristics and good visual outcome at month 12

Timeframe: 12 months

Trial details

NCT IDNCT03699618

SponsorJohns Hopkins University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-01-06

View on ClinicalTrials.gov More Submacular Hemorrhage trials